Evogliptin Clinical Trials (2026): 20 Studies for Diabetes Mellitus, Type 2 & Type2 Diabetes
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
20 Evogliptin clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 11 indications (including Diabetes Mellitus, Type 2 & Type2 Diabetes) and 4,622 total planned enrollment. 4 Phase 3 Evogliptin trials and 2 Phase 2, 7 Phase 4 are listed. Most recent activity: NCT05143177 (Dec 2026).
Evogliptin clinical trials at a glance: phase × recruitment status
| Phase | completed | suspended | unknown | Total |
|---|---|---|---|---|
| P1 | 5 | 5 | ||
| P2 | 2 | 2 | ||
| P2/P3 | 1 | 1 | ||
| P3 | 4 | 4 | ||
| P4 | 2 | 5 | 7 | |
| N/A | 1 | 1 |
Evogliptin clinical trials by indication
Type2 Diabetes (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04170998 | — | P3 | completed | Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control |
| NCT03910361 | — | P4 | completed | Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases |
| NCT03766724 | — | P1 | completed | Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults |
| NCT02974504 | EVERGREEN | P4 | completed | Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN) |
| NCT02954822 | — | P1 | completed | Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5mg and Glimepiride 4mg |
Diabetes Mellitus, Type 2 (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04653779 | — | P4 | unknown | A Clinical Trial to Evaluate the Preference Regarding Convenience of Medication and Efficacy/Safety of SUGAMET®XR Tablet 5/1000mg |
| NCT04326166 | — | N/A | unknown | Observational Study to Evaluate the Efficacy and Safety of Suganon Tab. or Sugamet XR Tab. |
| NCT02689362 | EVOLUTION | P2 | completed | Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2) |
| NCT02587975 | — | P4 | unknown | Effect of Evogliptin on Bone Metabolism in Human |
Type 2 Diabetes (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04356742 | — | P3 | completed | Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control |
| NCT02753803 | — | P1 | completed | Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mg |
Type 2 Diabetes Mellitus (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02949193 | — | P3 | completed | Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 Diabetes |
| NCT02946541 | — | P3 | completed | A Clinical Trial to Investigate the Efficacy and Safety of Evogliptin |
Calcific Aortic Valve Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05143177 | EVOID-AS | P2/P3 | suspended | A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS) |
Bone Diseases, Metabolic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04706637 | EVOMETA | P4 | unknown | A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin |
CAVD (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04521452 | — | P4 | unknown | Randomized, Open-label Trial of Inhibitory Effect of Evogliptin on Progression of CAVD |
Hepatitis B, Chronic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05473806 | — | P4 | unknown | Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes |
Hemodialysis Patients (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04195919 | — | P1 | completed | The Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis Patients |
Type2 Diabetes Mellitus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03667300 | DA1229 | P2 | completed | Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency |
Liver Dysfunction (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02754219 | — | P1 | completed | Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction |
Evogliptin pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| EVOMETA | NCT04706637 | P4 | unknown | Bone Diseases, Metabolic | 120 | — |
| EVERGREEN | NCT02974504 | P4 | completed | Type2 Diabetes | 207 | — |
| DA1229 | NCT03667300 | P2 | completed | Type2 Diabetes Mellitus | 209 | — |
| EVOLUTION | NCT02689362 | P2 | completed | Diabetes Mellitus, Type 2 | 146 | PMID 31890041 |
Terminated and withdrawn Evogliptin trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT05143177suspendedA Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)
All Evogliptin trials (20)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05143177 | EVOID-AS | A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS) | P2/P3 | suspended | 580 | REDNVIA Co., Ltd. | Jun 2022 |
| NCT04521452 | Randomized, Open-label Trial of Inhibitory Effect of Evogliptin on Progression of CAVD | P4 | unknown | 218 | Asan Medical Center | Sep 2020 | |
| NCT05473806 | Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes | P4 | unknown | 28 | Seung Up Kim | Sep 2020 | |
| NCT04706637 | EVOMETA | A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin | P4 | unknown | 120 | Kyung Hee University Hospital at Gangdong | Feb 2021 |
| NCT04356742 | Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control | P3 | completed | 198 | Dong-A ST Co., Ltd. | May 2020 | |
| NCT04170998 | Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control | P3 | completed | 283 | Dong-A ST Co., Ltd. | Jan 2020 | |
| NCT04653779 | A Clinical Trial to Evaluate the Preference Regarding Convenience of Medication and Efficacy/Safety of SUGAMET®XR Tablet 5/1000mg | P4 | unknown | 54 | Dong-A ST Co., Ltd. | Dec 2020 | |
| NCT04326166 | Observational Study to Evaluate the Efficacy and Safety of Suganon Tab. or Sugamet XR Tab. | — | unknown | 1,971 | Dong-A ST Co., Ltd. | Mar 2020 | |
| NCT04195919 | The Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis Patients | P1 | completed | 17 | Dong-A ST Co., Ltd. | Jul 2020 | |
| NCT03910361 | Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases | P4 | completed | 51 | Dong-A ST Co., Ltd. | Apr 2019 | |
| NCT03667300 | DA1229 | Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency | P2 | completed | 209 | Samsung Medical Center | Mar 2017 |
| NCT03766724 | Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults | P1 | completed | 42 | Dong-A ST Co., Ltd. | Nov 2018 | |
| NCT02689362 | EVOLUTION | Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2) | P2 | completed | 146 | Eurofarma Laboratorios S.A. | Aug 2017 |
| NCT02974504 | EVERGREEN | Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN) | P4 | completed | 207 | Dong-A ST Co., Ltd. | Sep 2016 |
| NCT02754219 | Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction | P1 | completed | 24 | Dong-A ST Co., Ltd. | Sep 2016 | |
| NCT02954822 | Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5mg and Glimepiride 4mg | P1 | completed | 36 | Dong-A ST Co., Ltd. | Nov 2016 | |
| NCT02587975 | Effect of Evogliptin on Bone Metabolism in Human | P4 | unknown | 20 | DongGuk University | Jun 2016 | |
| NCT02753803 | Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mg | P1 | completed | 36 | Dong-A ST Co., Ltd. | Jul 2016 | |
| NCT02949193 | Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 Diabetes | P3 | completed | 222 | Dong-A ST Co., Ltd. | May 2013 | |
| NCT02946541 | A Clinical Trial to Investigate the Efficacy and Safety of Evogliptin | P3 | completed | 160 | Dong-A ST Co., Ltd. | Jul 2013 |
Evogliptin clinical trials: frequently asked questions
- How many Evogliptin clinical trials are there?
- 20 Evogliptin clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 13 are marked completed.
- Are Evogliptin clinical trials recruiting in 2026?
- No active Evogliptin trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
- What conditions is Evogliptin being studied for?
- Evogliptin is being studied for Diabetes Mellitus, Type 2, Type2 Diabetes, Type 2 Diabetes, Type 2 Diabetes Mellitus, Diabetes Mellitus and 15 more. The trials are grouped by indication on this page.
- What phase is Evogliptin in?
- Evogliptin clinical trials span 7 Phase 4, 4 Phase 3, 2 Phase 2, 5 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Evogliptin clinical trials?
- The lead sponsor across the most Evogliptin trials is Dong-A ST Co., Ltd., with 7 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Evogliptinas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: